Table 1.
Demographic, clinical characteristics of recipients and donors, intraoperative details, and postoperative clinical course
| Full cohort (n = 261) | Propensity score matched cohort (n = 170) | |||||
|---|---|---|---|---|---|---|
| T-tube group (n = 129) | No-T-tube group (n = 132) | p | T-tube group (n = 85) |
No-T-tube group (n = 85) | p | |
| Donor and graft characteristics | ||||||
| Age (years) | 64 [52–73] | 57 [43–64] | <0.001 | 59 [46–71] | 59 [47–66] | 0.961 |
| BMI | 24.9 [23.1–27.1] | 24.8 [23.1–27.5] | 0.799 | 24.5 [22.5–27.4] | 25.0 [23.4–28.3] | 0.183 |
| Pre-donation ALT (U/L) | 26 [15–59] | 26 [16–71] | 0.687 | 27 [16–61] | 26 [16–44] | 0.557 |
| Pre-donation AST (U/L) | 29 [20–64] | 30 [21–49] | 0.990 | 31 [27–67] | 29 [21–48] | 0.639 |
| Pre-donation gGT (U/L) | 35 [14–70] | 33 [15–155] | 0.303 | 36 [14–82] | 36 [15–161] | 0.381 |
| Pre-donation ALP (U/L) | 65 [51–106] | 66 [51–95] | 0.878 | 63 [47–126] | 65 [51–88] | 0.756 |
| Pre-donation sodium (mMol/L) | 150 [144–154] | 150 [146–156] | 0.349 | 151 [144–154] | 150 [146–156] | 0.404 |
| Pre-donation lactates (mMol/L) | 0.9 [0.6–1.2] | 0.7 [0.6–1.2] | 0.478 | 0.9 [0.7–1.1] | 0.8 [0.6–1.4] | 0.875 |
| ICU-length of stay (days) | 4 [2–6] | 4 [3–8] | 0.175 | 4 [2–6] | 4 [2–7] | 0.332 |
| CIT (min) | 485 [405–576] | 450 [378–540] | 0.033 | 482 [405–575] | 465 [390–550] | 0.218 |
| WIT (min) | 40 [32–51] | 42 [32–53] | 0.403 | 40 [30–45] | 42 [32–50] | 0.484 |
| DRI | 1.76 [1.51–2.07] | 1.52 [1.27–1.96] | 0.008 | 1.73 [1.44–1.98] | 1.69 [1.37–2.01] | 0.777 |
| BAR score | 7 [4–10] | 5 [3–8] | 0.061 | 7 [4–10] | 7 [4–8] | 0.620 |
| Donor-recipient sex mismatch (%) | 53 (41.1%) | 47 (35.6%) | 0.363 | 37 (43.5%) | 34 (40%) | 0.641 |
| BSAi | 0.98 [0.90–1.05] | 0.99 [0.90–1.07] | 0.293 | 0.98 [0.90–1.05] | 1.0 [0.90–1.06] | 0.293 |
| Recipient characteristics | ||||||
| Age (years) | 57 [51–61] | 57 [51–62] | 0.876 | 56 [49–62] | 57 [51–63] | 0.313 |
| Male sex (%) | 102 (79.1%) | 108 (81.2%) | 0.756 | 65 (74.5%) | 71 (83.5%) | 0.250 |
| BMI | 25.1 [23.0–27.6] | 25.1 [22.1–28.1] | 0.972 | 25 [23.0–27.4] | 26 [22.7–27.9] | 0.485 |
| MELD score | 17 [12–24] | 15 [11–21] | 0.075 | 16 [11–22] | 16 [11–21] | 0.423 |
| Child–Pugh class C (%) | 60 (47.6%) | 42 (33.6%) | 0.024 | 39 (45.8%) | 32 (37.6%) | 0.276 |
| Operative time (min) | 385 [330–440] | 375 [320–435] | 0.570 | 385 [330–430] | 365 [330–430] | 0.816 |
| Packed red blood cell transfusion (IU) | 4 [2–8] | 4 [2–8] | 0.630 | 4 [1–8] | 5 [2–8] | 0.376 |
| Fresh-frozen plasma transfusion (ml) | 1800 [600–3000] | 1200 [600–2500] | 0.187 | 1400 [600–3000] | 1200 [600–2500] | 0.484 |
| EAD-O | 46 (35.6%) | 17 (13.5%) | <0.001 | 29 (34.1%) | 16 (19.0%) | 0.027 |
| MEAF | 4.5 [3.4–5.8] | 3.5 [2.7–4.7] | <0.001 | 4.5 [3.5–5.7] | 3.7 [2.9–5.0] | 0.014 |
Bold values indicate statistical significance
ALP Alkaline phosphatase, ALT Alanine transaminase, AST Aspartate transaminase, BAR balance of risk, BMI body mass index, BSAi body surface area index, CIT cold ischemia time, DRI donor risk index, EAD-O early allograft dysfunction according to Olthoff et al.’s definition, gGT Gamma-glutamyltransferase, HCC hepatocellular carcinoma, ICU intensive care unit, LT liver transplantation, MELD model for end-stage liver disease, MEAF Model for Early Allograft Function, WIT warm ischemia time